Table 5.
Nuclear expression of the proteins in angiogenic versus non-angiogenic NSCLCs
| Protein | Intensity percentage score (IPS) of protein expression | P value | Tumour type with higher expression | |
|---|---|---|---|---|
| Angiogenic tumours | Non-angiogenic tumours | |||
| HIF1 | 5.49 ± 0.31 | 3.79 ± 0.39 | 0.01 | Angiogenic |
| VEGFA | 6.09 ± 0.52 | 5.62 ± 0.32 | 0.74 | – |
| TYMP | 1.94 ± 0.22 | 1.16 ± 0.21 | 0.42 | – |
| KDR | 231.20 ± 8.55 | 229.80 ± 9.88 | >0.05 | – |
| KDRp34 | 11.69 ± 0.16 | 11.45 ± 0.39 | 0.77 | – |
| FIH | 7.50 ± 0.35 | 8.15 ± 0.72 | 0.50 | – |
| PHD1 | 3.10 ± 0.34 | 2.50 ± 0.35 | 0.99 | – |
| PHD2 | 2.56 ± 0.27 | 1.41 ± 0.35 | 0.02 | Angiogenic |
| PHD3 | 2.18 ± 0.13 | 0.65 ± 0.20 | <0.001 | Angiogenic |
| CXCR4 | 5.13 ± 0.23 | 3.72 ± 0.37 | <0.01 | Angiogenic |
| EPHB2 | 3.26 ± 0.26 | 4.91 ± 0.35 | <0.001 | Non-angiogenic |
| EPBH3 | 99.27 ± 7.41 | 147.30 ± 9.23 | <0.001 | Non-angiogenic |
| EPHB4 | 5.56 ± 0.30 | 5.73 ± 0.34 | 0.81 | – |
| SOD1 | 4.21 ± 0.45 | 5.00 ± 0.91 | 0.44 | – |
| C-FOS | 7.50 ± 0.52 | 5.53 ± 0.75 | 0.05 | Angiogenic |
| EGF | 235.20 ± 5.60 | 214.8 ± 8.68 | 0.01 | Angiogenic |
| FGF | 7.51 ± 0.38 | 8.68 ± 0.76 | 0.11 | – |
| BNIP3 | 3.96 ± 0.40 | 0.00 ± 0.00 | <0.001 | Angiogenic |
| P53 | 2.66 ± 0.36 | 2.32 ± 0.53 | 0.91 | – |
| PI3 | 0.53 ± 0.13 | 0.00 ± 0.00 | <0.02 | Angiogenic |
| SP1 | 5.31 ± 0.46 | 4.04 ± 0.60 | 0.24 | – |
| STAT3 | 7.80 ± 0.39 | 6.31 ± 0.81 | 0.09 | – |
| MEF2D | 251 ± 4.62 | 243.10 ± 8.04 | 0.38 | – |
| JMY | 2.01 ± 0.17 | 2.60 ± 0.27 | 0.07 | – |
| TRAP1 | 1.57 ± 0.18 | 4.58 ± 0.32 | <0.001 | Non-angiogenic |
| GST | 243.30 ± 6.15 | 244.10 ± 10.91 | 0.55 | – |
| CHGA | 0.00 ± 0.00 | 0.34 ± 0.12 | >0.05 | – |
All data are presented as mean ± standard error
HIF hypoxia-inducible factor; CA9 carbonic anhydrase 9; VEGFA vascular endothelial growth factor A; TYMP thymidine phosphorylase; KDR vascular endothelial growth factor receptor 2; KDRp34 vascular endothelial growth factor p34; FIH factor-inhibiting HIF; PHD prolyl hydroxylasedehydrogenase; DLL4 Delta-like 4; TSP1 thymidine phosphorylase 1; CXCR4 chemokine (C-X-C motif) receptor 4; EPH ephrin; SOD1 superoxide dismutase 1; BCL2 B cell lymphoma 2; FOS FBJ murine osteosarcoma viral oncogene homolog; EGF epidermal growth factor; EGFR epidermal growth factor receptor; BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3; PI3 peptidase inhibitor 3; SP1 Sp1 transcription factor; STAT3 signal transducer and activator of transcription 3; LON Lon protease; MEF2D myocyte enhancer factor 2D; JMY junction-mediating and regulatory protein, p53 cofactor; TRAP1 TNF receptor-associated protein 1; GST glutathione S-transferase; NCAM neural cell adhesion molecule; CHGA chromogranin A; SYP synaptophysin
– Indicates equal expression